Journal Club

2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

 

2021

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-1930.08.2021 (Mihaela Sava)
Kalil A.C. et al.: Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 N Engl J Med Vol. 384 No. 9 795-807 2021
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-1923.08.2021 (Simon Egli)
O’Brien M.P. et al.: Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 NEJM published on August 4, 2021, at NEJM.org - 2021
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales16.08.2021 (Sabine Kuster)
Falcone M. et al.: Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales Clin Infect Dis 2021 Jun 1;72(11) 1871-1878 2021
Antibiotic Therapy for 6 or 12 Weeks for Prosthetic 09.08.2021 (Richard Kühl)
Bernard L. et al.: Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection NEJM 384 (21) 1999 - 2001 2021
Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract InfectionA Randomized Clinical Trial02.08.2021 (Capoferri Gioele)
Dimitri M. et al.: Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract InfectionA Randomized Clinical Trial JAMA 326, Number 4 324-331 2021
Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis26.07.2021 (Andreas Neumayr)
Lau A. et al.: Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis N Engl J Med 384 2418 - 2427 2021
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial19.07.2021 (Ana Durovic) 
Bassetti M et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Lancet Infect Dis 2021 21 226-40 2021
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial medRxiv preprint05.07.2021 (Pascal Urwyler)
Horby P.W. et al.: Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial medRxiv preprint June 16, 2021
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients28.06.2021 (Ana Durovic)
Kamar N et al.: Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients NEJM DOI: 10.1056/NEJMc2108861 2021
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. A Randomized Clinical Trial14.06.2021 (Silvio Ragozzino)
Cohen MS et al.: Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. A Randomized Clinical Trial JAMA June 3, 2021. Online ahead of print.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis07.06.2021 (Anne-Valérie Burgener)
S.E. Dorman: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis NEJM 384 1705-1718 2021
Pujol M. et al.: Daptomycin plus Fosfomycin versus Daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial31.05.2021 (Andreas Neumayr)
Pujol M. et al.: Daptomycin plus Fosfomycin versus Daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial Clin Infect Dis 72 1517–25 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/ VESTED)17.05.2021 (Mihaela Sava)
Lockman S, Brummel S et al.: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/ VESTED) The Lancet 397 1276-92 2021
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.10.05.2021 (Capoferri Gioele)
François B. et al.: Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. SAATELLITE Studie Online Online 2021
Discontinuing Beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial03.05.2021 (Elisabeth Wehrle)
Dinh A. et al.: Discontinuing Beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial The Lancet 397 1195-1203 2021
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination26.04.2021 (Simon Egli)
R. R. Goel et al.: Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Sci. Immunol. Vol. 6, Issue 58 noch nicht definitiv 2021
1) Effectiveness of adjunctive clindamycin in beta-lactam antibiotic-treated patients with invasive beta-haemolytic streptococcal infections in US hospitals: a retrospective multicenter cohort study
2) Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections: A Multicenter Prospective Study

19.04.2021 (Sabine Kuster)
1) Babiker A et al. 2) Bruun T et al.: 1) Effectiveness of adjunctive clindamycin in beta-lactam antibiotic-treated patients with invasive beta-haemolytic streptococcal infections in US hospitals: a retrospective multicenter cohort study 
2) Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections: A Multicenter Prospective Study 1) Lancet Infect Dis 2) Clin Infect Dis 1) Published online December 14, 2020 2) Volume 72, Issue 2 1) 1-13 2) 293-300 1) 2020 2) 2021, January 15

 

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study12.04.2021 (Pascal Urwyler)
Hansen C. H. et al.: Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study Lancet  397 1204–12 2021
Attributes and predictors of long COVID29.03.2021 (Aurélien Martinez)
Sudre C et al.: Attributes and predictors of long COVID Nature medicine 2021
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study22.03.2021 (von Rotz Matthias)
Challen R. et al.: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study BMJ 372:n579 1-10 2021
Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: A pooled cohort study15.03.2021 (Richard Kühl)
Louise Thorlacius-Ussing et al.: Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: A pooled cohort study CID Online ahead of print: 2021 Mar 2;ciab201.
doi: 10.1093/cid/ciab201. 2021
1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
08.03.2021 (Silvio Ragozzino)
1) Gordon A.C. et al. 2) Horby P.W. et al.:
1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

1) NEJM, February 25, 2021
2) MedRxiv (preprint), February 11, 2021
Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study01.03.2021 (Andreas Neumayr)
Neumayr A. et al.: Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study
1)    Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020
2)    Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey
3)    The contribution of nosocomial infections to the first wave
22.02.2021 (Ana Durovic)
1)    Hall V et al
2)    Koen B Pouwels, Thomas House et al:
1)    Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020
2)    Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey
3)    The contribution of nosocomial infections to the first wave

1)    medRxiv preprint: https://doi.org/10.1101/2021.01.13.21249642
2)    Lancet Public Health https://doi.org/10.1016/S2468-2667(20)30282-6
3)    63.+78. SAGE meeting on COVID-19
2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial15.02.2021 (Mihaela Sava)
Maertens JA et al.: Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial The Lancet 397 499-509 2021
Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine08.02.2021 (Anne-Valérie Burgener)
J. Sadoff et al.: Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine NEJM Januray 13, 2021. DOI:10.1056/NEJMoa2034201 2021
Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections01.02.2021 (Pascal Urwyler)
Marks L.R. et al.: Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections Clinical Infectious Diseases 71(10) 650–6 2020
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance25.01.2021 (Sabine Kuster)
Koehler P et al.: Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis Published online, December 14 1-14 2020
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis18.01.2021 (Aurélien Martinez)
Francesca Conradie et al.: Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
The New England Journal of Medicine 382 893-302 2021
Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers11.01.2021 (Sandra Zingg)
Lumley S.F. et al: Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers NEJM Decemeber 23, 2020